U.S. markets closed

Karyopharm Therapeutics Inc. (KPTI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.33-0.04 (-0.48%)
At close: 4:00PM EDT

Karyopharm Therapeutics Inc.

85 Wells Avenue
2nd Floor
Newton, MA 02459
United States
617 658 0600
http://www.karyopharm.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees432

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard A. Paulson M.B.A.Pres, CEO & Director52.38kN/A1967
Dr. Sharon ShachamCo-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board720.1kN/A1970
Dr. Michael G. KauffmanCo-Founder, Sr. Clinical Advisor & Director986.25kN/A1963
Mr. Michael P. Mason CPA, M.B.A.Sr. VP, CFO & Treasurer583.63kN/A1975
Dr. Mansoor Raza MirzaClinical Consultant, Member of Scientific Advisory Board & Director140.6kN/A1961
Mr. Ran FrenkelExec. VP & Chief Devel. OfficerN/AN/A1969
Mr. Cameron PetersVP of Fin., Assistant Treasurer & Principal Accounting OfficerN/AN/A1960
Mr. Pierre S. Sayad M.S., Ph.D.VP of Global Medical & Scientific AffairsN/AN/AN/A
Mr. Michael J. Mano J.D.Sr. VP, Gen. Counsel & Sec.N/AN/A1975
Ms. Lisa Meletta J.D.VP of Legal & Chief Compliance OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition, the company's SINE compounds also show biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Further, it also has various investigational programs in clinical or preclinical development. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Corporate Governance

Karyopharm Therapeutics Inc.’s ISS Governance QualityScore as of July 1, 2021 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.